Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Charles River Laboratories International, Inc.    CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(CRL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/12/2021 01/13/2021 01/14/2021 01/15/2021 01/19/2021 Date
268.24(c) 267.49(c) 266.91(c) 273.72(c) 278.89(c) Last
336 372 253 234 369 085 330 960 376 014 Volume
-2.92% -0.28% -0.22% +2.55% +1.89% Change
More quotes
Financials (USD)
Sales 2020 2 891 M - -
Net income 2020 296 M - -
Net Debt 2020 1 565 M - -
P/E ratio 2020 47,4x
Yield 2020 -
Sales 2021 3 193 M - -
Net income 2021 360 M - -
Net Debt 2021 1 148 M - -
P/E ratio 2021 39,4x
Yield 2021 -
Capitalization 13 873 M 13 873 M -
EV / Sales 2020 5,34x
EV / Sales 2021 4,70x
Nbr of Employees 17 100
Free-Float 98,2%
More Financials
Company
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in... 
More about the company
Notations Surperformance© of Charles River Laboratories International, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
08:32aCHARLES RIVER LABORATORIES INTERNATI : Schedules Fourth-Quarter 2020 Earnings an..
BU
01/14CHARLES RIVER LABORATORIES INTERNATI : Collaborates With China-Based Jade Biomed..
MT
01/14CHARLES RIVER LABORATORIES INTERNATI : Partners with JADE Biomedical to Expand B..
BU
01/12CHARLES RIVER LABORATORIES INTERNATI : at J.P. Morgan Healthcare Conference Pres..
PU
01/11CHARLES RIVER LABORATORIES INTERNATI : to Present at J.P. Morgan Healthcare Conf..
BU
01/11Kavango Resources Appoints New Chairman
MT
01/06CHARLES RIVER LABORATORIES INTERNATI : Insider at Charles River Labs Internation..
MT
01/05INSIDER TRENDS : 90-Day Insider Buying Trend at Charles River Labs International..
MT
01/04CHARLES RIVER LABORATORIES INTERNATI : Purchases Distributed Bio For $83 Million..
MT
01/04CHARLES RIVER LABORATORIES INTERNATI : Acquires Distributed Bio
BU
2020CHARLES RIVER LABORATORIES INTERNATI : Argus Adjusts Charles River Laboratories ..
MT
2020CHARLES RIVER LABORATORIES INTERNATI : Citigroup Downgrades Charles River to Neu..
MT
2020CHARLES RIVER LABORATORIES INTERNATI : Delivers Industry-First Deciphex Patholyt..
BU
2020UK Network Companies' Innovation Projects Awarded GBP57.6 Million
DJ
2020KeyBanc Adjusts Charles River Laboratories International's Price Target to $2..
MT
More news
News in other languages on CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
01/04Quels ETF choisir pour investir dans les valeurs moyennes ?
2020CHARLES RIVER LABORATORIES INTERNATI : publication des résultats annuels
2020CHARLES RIVER LABORATORIES INTERNATI : Veröffentlichung des Jahresergebnisses
2017CHARLES RIVER LABORATORIES INTL : annonce la réussite d'un projet de recherche i..
2014CHARLES RIVER LABORATORIES : publication des résultats trimestriels
More news
Analyst Recommendations on CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
More recommendations
Stock Trading Strategies
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. - 2020
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Chart CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Duration : Period :
Charles River Laboratories International, Inc. Technical Analysis Chart | CRL | US1598641074 | MarketScreener
Technical analysis trends CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Average target price 260,50 $
Last Close Price 278,89 $
Spread / Highest target 3,98%
Spread / Average Target -6,59%
Spread / Lowest Target -44,4%
EPS Revisions
Managers and Directors
NameTitle
James C. Foster Chairman, President & Chief Executive Officer
David Ross Smith Chief Financial Officer & Executive Vice President
Shanna L. Cotti-Osmanski Chief Information Officer
George E. Massaro Independent Director
George M. Milne Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.9.55%13 873
MODERNA, INC.19.66%49 468
LONZA GROUP AG1.97%48 472
CELLTRION, INC.-13.37%38 667
IQVIA HOLDINGS INC.5.47%36 230
SEAGEN INC.7.75%34 149